Evaluation of the Efficacy of Oral Immunotherapy With Raw Apple in Patients Allergic to Birch Pollen and Apple: Prospective, Multicenter, Comparative Phase III Study

Apple-birch pollen-food allergy syndrome is particularly common in Northern and Central Europe (70% of patients allergic to birch pollen), and classically induces an oral syndrome that impairs patients' quality of life. Current treatment is based on food avoidance. However, evidence of the efficacy of this treatment is limited (small numbers, lack of validation with a control group, absence of double-blind evaluation of the primary endpoint in a challenge test against placebo). The aim of oral immunotherapy with raw apple is to improve the management of allergic patients by enabling them to acquire tolerance to raw apple and other rosacea.

NCT Number	NCT06771791
Lead Sponsor	University Hospital, Strasbourg, France
Conditions	Allergies
Enrollment	110 participants
Start Date	2025-01-08
Primary Completion	2027-05-05 (estimated)
Study Completion	2027-05-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-26